Wall Street Zen Downgrades Nanovibronix (NASDAQ:FEED) to Sell

Nanovibronix (NASDAQ:FEED) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Separately, Weiss Ratings assumed coverage on Nanovibronix in a research note on Tuesday, January 27th. They issued a “sell (e+)” rating on the stock. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Nanovibronix Stock Up 20.4%

NASDAQ:FEED opened at $2.01 on Friday. The company has a market cap of $2.19 million, a P/E ratio of -0.05 and a beta of 2.26. Nanovibronix has a 12-month low of $0.99 and a 12-month high of $162.50.

Insiders Place Their Bets

In related news, major shareholder Christian Michael Glibert acquired 240,000 shares of Nanovibronix stock in a transaction that occurred on Wednesday, January 14th. The stock was acquired at an average price of $2.67 per share, with a total value of $640,800.00. Following the completion of the acquisition, the insider directly owned 240,000 shares of the company’s stock, valued at $640,800. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.20% of the stock is owned by insiders.

About Nanovibronix

Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies.